NASDAQ:CLDX

Celldex Therapeutics (CLDX) Stock Forecast, Price & News

$33.19

+1.06 (+3.30%)

(As of 06/2/2023 ET)

Compare

Today's Range: $31.70
▼
$33.25
50-Day Range: $30.29
▼
$36.62
52-Week Range: $19.85
▼
$48.40

Volume: 369,489 shs
Average Volume: 369,020 shs
Market Capitalization: $1.57 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $63.50

Celldex Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 91.3% Upside
$63.50 Price Target
Short Interest: Bearish
11.47% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.77
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.64) to ($2.91) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.63 out of 5 stars

Medical Sector

832nd out of 983 stocks

Diagnostic Substances Industry

12th out of 15 stocks

3.5

Analyst's Opinion

Consensus Rating
Celldex Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $63.50, Celldex Therapeutics has a forecasted upside of 91.3% from its current price of $33.19.
Amount of Analyst Coverage
Celldex Therapeutics has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
11.47% of the outstanding shares of Celldex Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Celldex Therapeutics has a short interest ratio ("days to cover") of 8.4.
Change versus previous month
Short interest in Celldex Therapeutics has recently increased by 1.12%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Celldex Therapeutics does not currently pay a dividend.
Dividend Growth
Celldex Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CLDX.

3.2

News and Social Media Coverage

News Sentiment
Celldex Therapeutics has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Celldex Therapeutics this week, compared to 2 articles on an average week.
Search Interest
9 people have searched for CLDX on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Celldex Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.70% of the stock of Celldex Therapeutics is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Celldex Therapeutics are expected to decrease in the coming year, from ($2.64) to ($2.91) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Celldex Therapeutics is -13.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Celldex Therapeutics is -13.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Celldex Therapeutics has a P/B Ratio of 5.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Celldex Therapeutics (NASDAQ:CLDX) Stock

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Receive CLDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CLDX Stock News Headlines

June 4, 2023 | americanbankingnews.com

StockNews.com Upgrades Celldex Therapeutics (NASDAQ:CLDX) to Sell

May 31, 2023 | markets.businessinsider.com

4 Analysts Have This to Say About Celldex Therapeutics

June 4, 2023 | Stocks To Trade (Ad)

15 A.I. Trading Opportunities a Day

Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.

May 31, 2023 | finance.yahoo.com

Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies

May 23, 2023 | finance.yahoo.com

Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

May 18, 2023 | seekingalpha.com

Celldex Therapeutics: Revolutionizing Cancer Care With Innovative Immunotherapies

May 15, 2023 | finance.yahoo.com

Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™

May 8, 2023 | americanbankingnews.com

Celldex Therapeutics (NASDAQ:CLDX) Price Target Cut to $54.00 by Analysts at Cantor Fitzgerald

June 4, 2023 | Legacy Research (Affiliate) (Ad)

“One-Stock Millionaire” IGNORES 99.9% of the Market

During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.

May 6, 2023 | msn.com

Cantor Fitzgerald Maintains Celldex Therapeutics (CLDX) Overweight Recommendation

May 5, 2023 | msn.com

HC Wainwright & Co. Reiterates Celldex Therapeutics (CLDX) Buy Recommendation

May 4, 2023 | msn.com

Celldex Therapeutics: Q1 Earnings Insights

May 4, 2023 | finance.yahoo.com

Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update

April 18, 2023 | finance.yahoo.com

Strength Seen in Celldex (CLDX): Can Its 7.1% Jump Turn into More Strength?

April 15, 2023 | americanbankingnews.com

Celldex Therapeutics (NASDAQ:CLDX) Sees Strong Trading Volume

April 12, 2023 | benzinga.com

Is Celldex Therapeutics, Inc. (CLDX) a Smart Choice in Biotechnology Monday?

April 12, 2023 | finance.yahoo.com

Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 42%?

April 12, 2023 | americanbankingnews.com

Celldex Therapeutics (NASDAQ:CLDX) Stock Price Down 4.4%

April 5, 2023 | americanbankingnews.com

Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Increases By 5.5%

March 23, 2023 | americanbankingnews.com

Celldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading Volume

March 23, 2023 | markets.businessinsider.com

LifeSci Capital Reaffirms Their Buy Rating on Celldex (CLDX)

March 22, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Celldex (CLDX)

March 2, 2023 | finanznachrichten.de

Celldex Therapeutics, Inc.: Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update

March 2, 2023 | finance.yahoo.com

Celldex Therapeutics Full Year 2022 Earnings: Revenues Beat Expectations, EPS In Line

March 1, 2023 | finance.yahoo.com

Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update

February 27, 2023 | msn.com

Celldex gains 12% on Phase 1 data for urticaria candidate

February 27, 2023 | benzinga.com

Why Celldex Therapeutics Shares Are Trading Higher Today

See More Headlines

CLDX Price History

30 days | 90 days | 365 days | Advanced Chart

CLDX Company Calendar

Last Earnings: 11/09/2021
Today: 6/03/2023
Next Earnings (Estimated): 8/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:CLDX
CUSIP: 15117B10
CIK: 744218
Web: www.celldex.com
Phone: (908) 454-7120
Fax: 908-454-1911
Employees: 132
Year Founded: 1983

Price Target and Rating

Average Stock Price Forecast: $63.50
High Stock Price Forecast: $73.00
Low Stock Price Forecast: $54.00
Forecasted Upside/Downside: +91.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.52)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-112,320,000.00
Net Margins: -3,766.22%
Pretax Margin: -3,766.22%
Return on Equity: -32.84%
Return on Assets: -30.35%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 19.03
Quick Ratio: 19.03

Sales & Book Value

Annual Sales: $2.36 million
Price / Sales: 664.50
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.41 per share
Price / Book: 5.18

Miscellaneous

Outstanding Shares: 47,250,000
Free Float: 45,504,000
Market Cap: $1.57 billion
Optionable: Optionable
Beta: 2.12

Social Links

Key Executives

Anthony S. Marucci
President, Chief Executive Officer & Director

Sam Martin
CFO, Secretary, Treasurer & Senior Vice President

Tibor Keler
Chief Scientific Officer & Executive VP

Diane C. Young
Chief Medical Officer & Senior Vice President

Elizabeth Crowley
Chief Product Development Officer & Senior VP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CLDX Stock - Frequently Asked Questions

Should I buy or sell Celldex Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLDX shares.
View CLDX analyst ratings or view top-rated stocks.
What is Celldex Therapeutics' stock price forecast for 2023?: 3 brokers have issued twelve-month price targets for Celldex Therapeutics' stock. Their CLDX share price forecasts range from $54.00 to $73.00. On average, they expect the company's share price to reach $63.50 in the next year. This suggests a possible upside of 91.3% from the stock's current price.
View analysts price targets for CLDX or view top-rated stocks among Wall Street analysts.
How have CLDX shares performed in 2023?: Celldex Therapeutics' stock was trading at $44.57 at the start of the year. Since then, CLDX stock has decreased by 25.5% and is now trading at $33.19.
View the best growth stocks for 2023 here.
When is Celldex Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our CLDX earnings forecast.
How were Celldex Therapeutics' earnings last quarter?: Celldex Therapeutics, Inc. (NASDAQ:CLDX) released its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.09. The biopharmaceutical company earned $0.15 million during the quarter, compared to analyst estimates of $1.70 million. Celldex Therapeutics had a negative net margin of 3,766.22% and a negative trailing twelve-month return on equity of 32.84%.
What ETFs hold Celldex Therapeutics' stock?: ETFs with the largest weight of Celldex Therapeutics (NASDAQ:CLDX) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY), Invesco DWA Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and iShares Micro-Cap ETF (IWC).
When did Celldex Therapeutics' stock split?: Celldex Therapeutics's stock reverse split on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Celldex Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX).
What is Celldex Therapeutics' stock symbol?: Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."
Who are Celldex Therapeutics' major shareholders?: Celldex Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (14.99%), Wellington Management Group LLP (8.85%), BlackRock Inc. (6.88%), State Street Corp (4.87%), Jennison Associates LLC (3.35%) and Geode Capital Management LLC (1.96%). Insiders that own company stock include Anthony S Marucci, Diane C Young, Elizabeth Crowley, Freddy A Jimenez, James J Marino, Margo Heath-Chiozzi, Richard M Wright, Samuel Bates Martin, Sarah Cavanaugh and Tibor Keler.
View institutional ownership trends.
How do I buy shares of Celldex Therapeutics?: Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Celldex Therapeutics' stock price today?: One share of CLDX stock can currently be purchased for approximately $33.19.
How much money does Celldex Therapeutics make?: Celldex Therapeutics (NASDAQ:CLDX) has a market capitalization of $1.57 billion and generates $2.36 million in revenue each year. The biopharmaceutical company earns $-112,320,000.00 in net income (profit) each year or ($2.52) on an earnings per share basis.
How many employees does Celldex Therapeutics have?: The company employs 132 workers across the globe.
How can I contact Celldex Therapeutics?: Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The official website for the company is www.celldex.com. The biopharmaceutical company can be reached via phone at (908) 454-7120, via email at ir@celldextherapeutics.com, or via fax at 908-454-1911.

This page (NASDAQ:CLDX) was last updated on 6/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial